Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine in Mild Cognitive Impairment
NCT00134953Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2003
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of rivastigmine in Mild Cognitive Impairment (MCI), sponsored by Novartis. Started Jan 2003; status: terminated.
02
Drugs
rivastigmine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00134953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134953.